(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
10 June 2004 (10.06.2004)

PCT

(10) International Publication Number
WO 2004/048378 A1

(51) International Patent Classification[7]: C07D 471/06, A61K 31/437, A61P 37/02

(21) International Application Number: PCT/SE2003/001805

(22) International Filing Date: 21 November 2003 (21.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

0203471-8	22 November 2002 (22.11.2002)	SE
60/428240	22 November 2002 (22.11.2002)	US
0301299-4	6 May 2003 (06.05.2003)	SE
0301851-2	25 June 2003 (25.06.2003)	SE
60/482122	25 June 2003 (25.06.2003)	US

(71) Applicant *(for all designated States except US)*: **ACTIVE BIOTECH AB** [SE/SE]; Scheelevägen 22, Box 724, S-220 07 Lund (SE).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: **MATTHEWS, Ian, Richard** [GB/GB]; c/o Avidex, 57C Milton Park, GB-Abingdon, Oxfordshire OX14 4RX (GB). **COULTER, Thomas, Stephen** [GB/GB]; Evotec OAI, 111 Milton Park, Abington, Oxon OX14 4SD (GB). **GHIRON, Chiara** [GB/GB]; Evotec OAI, 151, Milton Park, Abingdon, Oxfordshire OX14 4SD (GB). **BRENNAN, Chris, James** [GB/GB]; Evotec OAI, 151, Milton Park, Abingdon, Oxfordshire OX14 4SD (GB). **UDDIN, Muhammed, Kamal** [GB/GB]; Evotec OAI, 151, Milton Park, Abingdon, Oxfordshire OX14 4SD (GB). **PETTERSSON, Lars, Olof, Göran** [SE/SE]; c/o Active Biotech Ab, Scheelevägen 22, S-220 07 Lund (SE). **THRIGE, Dorthe da Graça** [DK/SE]; c/o Active Biotech AB, Scheelevägen 22, S-220 07 Lund (SE). **HUXLEY, Philip** [GB/GB]; 57c Milton Park, Abingdon, Oxfordshire OX14 4RX (GB).

(74) Agent: **AWAPATENT AB**; Box 5117, S-200 71 Mälmo (SE).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ (utility model), CZ, DE (utility model), DE, DK (utility model), DK, DM, DZ, EC, EE (utility model), EE, EG, ES, FI (utility model), FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:
— *with international search report*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: PYRAZOLOQUINOLINES WITH IMMUNOMODULATING ACTIVITY

(57) Abstract: The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.

WO 2004/048378 A1

Pyrazoloquinolines with immunomodulating activity

The present invention relates to novel heterocyclic compounds, to methods for their preparation, to compositions containing them, and to methods and use for clinical treatment of medical conditions which may benefit from immunomodulation, including rheumatoid arthritis, multiple sclerosis, diabetes, asthma, transplantation, systemic lupus erythematosis and psoriasis. More particularly the present invention relates to novel heterocyclic compounds, which are CD80 antagonists capable of inhibiting the interactions between CD80 and CD28.

Background of the invention

The immune system possesses the ability to control the homeostasis between the activation and inactivation of lymphocytes through various regulatory mechanisms during and after an immune response. Among these are mechanisms that specifically inhibit and/or turn off an immune response. Thus, when an antigen is presented by MHC molecules to the T-cell receptor, the T-cells become properly activated only in the presence of additional co-stimulatory signals. In the absence of accessory signals there is no lymphocyte activation and either a state of functional inactivation termed anergy or tolerance is induced, or the T-cell is specifically deleted by apoptosis. One such co-stimulatory signal involves interaction of CD80 on specialised antigen-presenting cells with CD28 on T-cells, which has been demonstrated to be essential for full T-cell activation. (Lenschow *et al.* (1996) *Annu. Rev. Immunol.*, 14, 233-258)

A paper by Erbe *et al*, in J. Biol. Chem. Vol. 277, No. 9, pp 7363-7368 (2002), describes three small molecule ligands which bind to CD80, and inhibit binding of CD80 to CD28 and CTLA4. Two of the disclosed ligands are fused pyrazolones of structures A and B:



A



B

DESCRIPTION OF THE INVENTION

According to the present invention there is provided a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:



(I)

wherein

R_1 and R_3 independently represent H; F; Cl; Br; $-NO_2$; $-CN$; C_1-C_6 alkyl optionally substituted by F or Cl; or C_1-C_6 alkoxy optionally substituted by F;

R_2 represents H, or optionally substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl or optionally substituted phenyl;

Y represents -O-, -S-, N-oxide, or $-N(R_5)-$ wherein R_5 represents H or C_1-C_6 alkyl;

X represents a bond or a divalent C_1-C_6 alkylene radical;

R_4 represents $-C(=O)NR_6R_7$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$, $-NHC(=O)NHR_6$, or $-NHC(=S)NHR_6$ wherein

R_6 represents H, or a radical of formula $-(Alk)_b-Q$ wherein b is 0 or 1, and

Alk is an optionally substituted divalent straight chain or branched C_1-C_{12} alkylene, C_2-C_{12} alkenylene or C_2-C_{12} alkynylene radical which may be interrupted by one or more non-adjacent -O-, -S- or -N(R_8)- radicals wherein R_8 represents H or C_1-C_4 alkyl, C_3-C_4 alkenyl, C_3-C_4 alkynyl, or C_3-C_6 cycloalkyl, and

Q represents H; $-CF_3$; -OH; -SH; $-NR_8R_8$ wherein each R_8 may be the same or different; an ester group; or an optionally substituted phenyl, C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and

R_7 represents H or C_1-C_6 alkyl; or when taken together with the atom or atoms to which they are attached R_6 and R_7 form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms.

Compounds of general formula (I) are CD80 antagonists. They inhibit the interaction between CD80 and CD28 and thus the activation of T cells, thereby modulating the immune response.

Accordingly the invention also includes:

(i) a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof for use in the treatment of conditions which benefit from immunomodulation.

(ii) the use of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof in the manufacture of a medicament for the treatment of conditions which benefit from immunomodulation,.

(iii) a method of immunomodulation in humans and non-human primates, comprising administration to a subject in need of such treatment an immunomodulatory effective dose of a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof.

(iv) a pharmaceutical or veterinary composition comprising a compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof together with a

pharmaceutically or veterinarily acceptable excipient or carrier.

Conditions which benefit from immunomodulation include:

Adrenal insufficiency
Allergic angiitis and granulomatosis
Amylodosis
Ankylosing spondylitis
Asthma
Autoimmune Addison's disease
Autoimmune alopecia
Autoimmune chronic active hepatitis
Autoimmune hemolytic anemia
Autoimmune neutropenia
Autoimmune thrombocytopenic purpura
Autoimmune vasculitides
Behçet's disease
Cerebellar degeneration
Chronic active hepatitis
Chronic inflammatory demyelinating polyradiculoneuropathy
Dermatitis herpetiformis
Diabetes
Eaton-Lambert myasthenic syndrome
Encephalomyelitis
Epidermolysis bullosa
Erythema nodosa
Gluten-sensitive enteropathy
Goodpasture's syndrome
Graft versus host disease
Guillain-Barre syndrome
Hashimoto's thyroiditis
Hyperthyrodism
Idiopathic hemachromatosis
Idiopathic membranous glomerulonephritis
Minimal change renal disease
Mixed connective tissue disease
Multifocal motor neuropathy

Multiple sclerosis
Myasthenia gravis
Opsoclonus-myoclonus syndrome
Pemphigoid
Pemphigus
Pernicious anemia
Polyarteritis nodosa
Polymyositis/dermatomyositis
Post-infective arthritides
Primary biliary sclerosis
Psoriasis
Reactive arthritides
Reiter's disease
Retinopathy
Rheumatoid arthritis
Sclerosing cholangitis
Sjögren's syndrome
Stiff-man syndrome
Subacute thyroiditis
Systemic lupus erythematosis
Systemic sclerosis (scleroderma)
Temporal arteritis
Thromboangiitis obliterans
Transplantation rejection
Type I and type II autoimmune polyglandular syndrome
Ulcerative colitis
Uveitis
Wegener's granulomatosis

As used herein the term "alkylene" refers to a straight or branched alkyl chain having two unsatisfied valencies, for example $-CH_2-$, $-CH_2CH_2-$, $-CH_2CH_2CH_2-$, $-CH(CH_3)CH_2-$, $-CH(CH_2CH_3)CH_2CH_2CH_3$, and $-C(CH_3)_3$.

As used herein the term "heteroaryl" refers to a 5- or 6- membered aromatic ring containing one or more heteroatoms. Illustrative of such groups are thienyl, furyl, pyrrolyl, imidazolyl, benzimidazolyl, thiazolyl, pyrazolyl, isoxazolyl, isothiazolyl, triazolyl, thia-

diazolyl, oxadiazolyl, pyridinyl, pyridazinyl, pyrimidinyl, pyrazinyl, triazinyl.

As used herein the unqualified term "heterocyclyl" or "heterocyclic" includes "heteroaryl" as defined above, and in particular means a 5-8 membered aromatic or non-aromatic heterocyclic ring containing one or more heteroatoms selected from S, N and O, including for example, pyrrolyl, furanyl, thienyl, piperidinyl, imidazolyl, oxazolyl, isoxazolyl, thiazolyl, thiadiazolyl, pyrazolyl, pyridinyl, pyrrolidinyl, pyrimidinyl, morpholinyl, piperazinyl, indolyl, morpholinyl, benzofuranyl, pyranyl, isoxazolyl, quinuclidinyl, aza-bicyclo[3.2.1]octanyl, benzimidazolyl, methylenedioxyphenyl, maleimido and succinimido groups.

Unless otherwise specified in the context in which it occurs, the term "substituted" as applied to any moiety herein means substituted with one or more of the following substituents, namely $(C_1\text{-}C_6)$alkyl, trifluoromethyl, $(C_1\text{-}C_6)$alkoxy (including the special case where a ring is substituted on adjacent ring C atoms by methylenedioxy or ethylenedioxy), trifluoromethoxy, $(C_1\text{-}C_6)$alkylthio, phenyl, benzyl, phenoxy, $(C_3\text{-}C_8)$cycloalkyl, hydroxy, mercapto, amino, fluoro, chloro, bromo, cyano, nitro, oxo, $-COOH$, $-SO_2OH$, $-CONH_2$, $-SO_2NH_2$, $-COR^A$, $-COOR^A$, $-SO_2OR^A$, $-NHCOR^A$, $-NHSO_2R^A$, $-CONHR^A$, $-SO_2NHR^A$, $-NHR^A$, $-NR^AR^B$, $-CONR^AR^B$ or $-SO_2NR^AR^B$ wherein R^A and R^B are independently a $(C_1\text{-}C_6)$alkyl group. In the case where "substituted" means substituted by $(C_3\text{-}C_8)$cycloalkyl, phenyl, benzyl or phenoxy, the ring thereof may itself be substituted with any of the foregoing, except $(C_3\text{-}C_8)$cycloalkyl phenyl, benzyl or phenoxy.

As used herein the unqualified term "carbocyclyl" or "carbocyclic" refers to a 5-8 membered ring whose ring atoms are all carbon.

Some compounds of the invention contain one or more chiral centres because of the presence of asymmetric carbon atoms. The presence of asymmetric carbon atoms gives

rise to stereoisomers or diastereoisomers with R or S stereochemistry at each chiral centre. The invention includes all such stereoisomers and diastereoisomers and mixtures thereof.

Salts of salt forming compounds of the invention include physiologically acceptable acid addition salts for example hydrochlorides, hydrobromides, sulphates, methane sulphonates, p-toluenesulphonates, phosphates, acetates, citrates, succinates, lactates, tartrates, fumarates and maleates; and base addition salts, for example sodium, potassium, magnesium, and calcium salts. Where the compound contains an amino group, quaternary amino salts are also feasable, and are included in the invention.

In the compounds of the invention the following are examples of the several structural variables:

R_1 may be, for example, H, F, Cl, methyl, methoxy, or methylenedioxy. Currently it is preferred that R_1 is H, Cl or especially F;

R_2 may be, for example H, methyl, methoxy, cyclopropyl, phenyl, or fluoro-, chloro-, methyl, or methoxy-substituted phenyl. H or cyclopropyl is presently preferred;

R_3 may be, for example, H, F, Cl, methyl, methoxy, or methylenedioxy. Currently it is preferred that R_3 is F or Cl, and it is most preferred that R_3 be H;

Y may be, for example, -O-, -S-, or $-N(R_5)-$ wherein R_5 represents H or methyl. -NH- or -S- is presently preferred.

X may be, for example a bond, or a $-CH_2-$ or $-CH_2CH_2-$ radical. A bond is presently preferred.

R_4 represents $-C(=O)NR_6R_7$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$, $-NHC(=O)NHR_6$, or $-NHC(=S)NHR_6$. Of these $-NR_7C(=O)R_6$, and especially $-C(=O)NR_6R_7$ and $-NHC(=O)NHR_6$ are curently preferred. R_7 is preferably H, but a wide range of R_6 substituents have given rise to highly active compounds

of the invention. Many exemplary R_6 substituents appear in the compounds of the Examples below.

R_6 may be, for example, H or a radical of formula $-Alk_b-Q$ wherein b is 0 or 1 and

Alk may be, for example a $-(CH_2)_n-$, $-CH((CH_2)_mCH_3)(CH_2)_n-$, $-C((CH_2)_mCH_3)((CH_2)_pCH_3)(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_m-$, $-(CH_2)_n-NH-(CH_2)_m-$, or $-(CH_2)_n-NH-(CH_2)_m-NH-(CH_2)_p-$ radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and

Q may represent H, -OH, $-COOCH_3$, phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl; and

R_7 may be, for example, H, or when taken together with the atom or atoms to which they are attached R_6 and R_7 may form a heterocyclic ring of 5, 6 or 7 members.

Specific examples of R_4 groups include those present in the compounds of the Examples herein.

Compounds of the invention may be prepared by synthetic methods known in the literature, from compounds which are commercially available or are accessible from commercially available compounds. For example, compounds of formula (I) wherein R_4 is a group $-NR_7C(=O)R_6$ may be prepared by acylation of an amine of formula (II) with an acid chloride of formula (III):



(II)



(III)

Compounds of the invention wherein R_4 is a group $-NHC(=O)NHR_6$ may be prepared by reaction of an amine of formula (IIA) with an isocyanate of formula (IIIA)



(IIA)



(IIIA)

Compounds of the invention wherein R_4 is a group $-C(=O)NHR_6$ may be prepared by reaction of an acid chloride of formula (IIB) with an amine NHR_6R_7:



(IIB)

Compounds of the invention wherein R_4 is a group $-NR_7C(=O)OR_6$ may be prepared by reaction of an amine of formula (II) with a chloroformate $ClC(=O)OR_6$.

The following Examples illustrate the preparation of compounds of the invention:

Preparation of Intermediate 1

2-(4-Nitrophenyl)-6-fluoro-2,5-dihydropyrazolo[4,3-c]-quinolin-3-one



4-Nitrophenylhydrazine (2.28 g, 0.014 mol) was added in one portion to a stirred solution of 4-chloro-8-fluoro-quinoline-3-carboxylic acid ethyl ester (3.58 g, 0.014 mol) in anhydrous n-butyl alcohol (50 ml) at room temperature. The mixture was refluxed for 16 h under nitrogen, cooled to room temperature and then filtered to leave an orange solid. The solid was purified by washing sequentially with ethyl acetate (20 ml) and heptane (20 ml) and then finally dried under suction to give the *pyrazolone* (3.93 g, 87 %) as a dark orange solid, LCMS m/z 325.24 $[M+H]^+$ @ R_T 1.47 min.

Preparation of Intermediate 2

2-(4-Aminophenyl)-6-fluoro-2,5-dihydropyrazolo[4,3-c]-quinolin-3-one



Tin (II) chloride dihydrate (12.5 g, 0.055 mol) was added in one portion to a stirred solution of 2-(4-nitrophenyl)-6-fluoro-2,5-dihydro-pyrazolo[4,3-c]quinolin-3-one (intermediate 1) (3.59 g, 0.011 mol) in ethyl alcohol (110 ml) at room temperature. The mixture was then heated

to 80 °C for 8 h, cooled to room temperature and filtered to leave a yellow solid. The solid was suspended in a biphasic solution of ethyl acetate (1L), a saturated solution of Rochelles salt (500 ml) and a saturated solution of sodium bicarbonate (500 ml) and stirred at room temperature for 2h. The mixture was filtered and the remaining solid was washed with water and dried under vacuum to afford the title compound (3.39 g, 99 %) as a bright yellow solid, LCMS m/z 295.30 $[M+H]^+$ @ R_T 0.84 min.

Example 1

N-[4-(6-Fluoro-3-oxo-3,5-dihydropyrazolo[4,3-c]quinolin-2-yl)-phenyl]-2-methyl-butyramide



(±)-2-Methylbutyryl chloride (13.6 µl, 0.11 mmol) was added dropwise over 30 sec to a stirred solution of 2-(4-amino-phenyl)-6-fluoro-2,5-dihydro-pyrazolo[4,3-c]quinolin-3-one (Intermediate 2) (30 mg, 0.10 mmol), triethylamine (14 µl, 0.11 mmol) and 4-dimethylaminopyridine (2.4 mg, 0.02 mmol) in dichloromethane (1 ml) at room temperature. The mixture was stirred at room temperature for 16 h. The yellow solid was then filtered and purified by washing sequentially with a saturated solution of sodium bicarbonate (1 ml), ethyl acetate (1 ml) and ethyl alcohol (0.5 ml) and finally dried under suction to give the title compound (10 mg, 26 %) as a bright yellow solid, LCMS m/z 379.36 $[M+H]^+$ @ R_T 1.18 min. δ_H(400 MHz, $(CD_3)_2SO$) 9.89 (1H, s), 8.52 (1H, s), 8.15 (2H, d *J* 9.0 Hz), 8.01 (1H, d *J* 7.0 Hz), 7.69 (2H, d *J* 9.0 Hz) 7.57-7.46 (2H, m), 2.46-2.39 (1H, m), 1.69-1.36 (2H, m), 1.11 (3H, d *J* 6.8 Hz), 0.91(3H, t *J* 7.3 Hz).

The title compound, and compounds of subsequent Examples, were tested in the assay described below in the Assay Section, to determine their activities as inhibitors of the CD80-CD28 interaction. The present title compound had an activity rating of ***.

Examples 2-49

The following compounds were synthesized by the route described in Example 1, substituting the appropriate acid chloride for (±)-2-methylbutyryl chloride:

Example 2

2-Methyl-pentanoic acid [4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-amide



δ_H(400 MHz, $(CD_3)_2SO$) 9.92 (1H, s), 8.53 (1H, s), 8.12 (2H, d *J* 9.2 Hz), 8.05 (1H, d *J* 7.6 Hz), 7.70 (2H, d *J* 9.2 Hz), 7.63-7.53 2H, m), 1.68-1.58 (1H, m), 1.38-1.28 (3H, m), 1.11 (3H, d *J* 6.6 Hz), 0.91 (3H, t *J* 7.1 Hz).

Activity ***

Example 3

1-Methyl-1H-pyrrole-2-carboxylic acid [4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-amide



δ_H(400 MHz, $(CD_3)_2SO$) 9.76 (1H, s), 8.50 (1H, s), 8.26 (2H, d 9.0 Hz), 7.97-7.94 (1H, m), 7.73 (2H, d *J* 9.0 Hz), 7.39-7.28 (2H, m), 7.07-7.01 (2H, m), 3.91 (3H, s).

Activity *

Example 4

N-[4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-3-methyl-butyramide



δ_H(400 MHz, $(CD_3)_2SO$) 9.92 (1H, s), 8.52 (1H, s), 8.14 (2H, d *J* 9.2 Hz), 8.01 (1H, d *J* 7.3 Hz), 7.67 (2H, d *J* 9.2 Hz), 7.57-7.47 (2H, m), 2.21 (2H, d *J* 6.8 Hz), 2.14-2.07 (1H, m), 0.96 (6H, d *J* 6.6 Hz).

Activity **

Example 5

2-Propyl-pentanoic acid [4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-amide



δ_H(400 MHz, $(CD_3)_2SO$) 9.93 (1H, s), 8.53 (1H, s), 8.11 (2H, d *J* 9.0 Hz), 8.05 (1H, d *J* 7.8 Hz), 7.70 (2H, d

J 9.0 Hz), 7.59-7.46 (2H, m), 2.46-2.35 (1H, m), 1.63-1.27 (4H, m), 0.90(6H, t *J* 7.1 Hz).

Activity *

Example 6

5-[4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl) phenylcarbamoyl]-pentanoic acid methyl ester



δ_H(400 MHz, $(CD_3)_2SO$) 9.85 (1H, s), 8.47 (1H, s), 8.25 (2H, d *J* 9.0 Hz), 7.91-7.90 (1H, m), 7.59 (2H, d *J* 9.0 Hz), 7.29-7.20 (2H, m), 3.61 (3H, s), 2.38-2.28 (4H, m), 1.64-1.50 (4H, m).

Activity ***

Example 7

N-[4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-2,2-dimethyl-propionamide



δ_H(400 MHz, $(CD_3)_2SO$) 9.26 (1H, s), 8.52 (1H, s), 8.15 (2H, d *J* 9.2 Hz), 8.03 (1H, d *J* 8.8 Hz), 7.71 (2H, d *J* 9.2 Hz), 7.56-7.47 (2H, m), 1.26 (9H, s).

Activity **

Examples 8 to 28 were also prepared by the method of Example 1 using the appropriate acid chloride:



Example	X	R	M.S. (MH+)	Activity
8	6-F		443.4	**
9	6-F	$-CH_2Cl$	371.31	**
10	6-F		389.34	*
11	6-F		485.45	*
12	6-F	CO_2Me	381.34	**
13	6-F	OEt	367.18	
14	6-F		507.43	*
15	6-F		466.41	**
16	6-F	Me	337.36	**
17	6-F	$CH(Et)CH_2CH_2CH_2Me$	421.46	*
18	6-F	$CH(Et)_2$	393.41	***

19	6-F		405.41	**
20	6-F		448.44	**
21	6-F		481.35	**
22	6-F		423.42	***
23	6-F	$(CH_2)_8CO_2Me$	493.51	**
24	6-F	iPr	365.36	***
25	6-F	$CH_2OCH_2CH_2OMe$	411.4	**
26	6-F	CH(Me)(nPr)	393.42	***
27	6-F	CH_2OMe	367.24	**
28	6-F		390.33	**
29	6-F	$CH_2CH_2CH_2N^+(Me)_3$	422.1(M+)	***
30	6-F	$CH_2CH_2CH_2N(Me)_2$	408.3	***
31	6-F	$CH_2NHCH_2CH_2CH_2N(Me)(Ph)$	499.3	*
32	6-F		485.3	*
33	6-F		505.1	***
34	6-F		517.2	***
35	6-F		477.1	***
36	6-F		457.1	**

37	6-F		463.1	**
38	6-F		438.3	**
39	6-F		463.2	***
40	6-F		460.4	**
41	6-F	$CH_2NHCH_2CH_2N(iPr)_2$	479.4	**
42	6-F		420.2	**
43	H	$CH(NH_2)CH_3$	348.3	**
44	H	CH(Me)nPr	375.3	*
45	H	iPr	347.3	**
46	6-F	$CH(NH_2)CH_3$	366.3	***
47	H	CH(Me)Et	361.3	**
48	6-F		529.1	**
49	6-F	$CH_2N(Me)CH_2Ph$	456.4	**

Preparation of Intermediate 3

3-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid



3-Hydrazinobenzoic acid (1.91 g, 0.013 mol) was added in one portion to a stirred solution of 4-chloro-8-fluoro-quinoline-3-carboxylic acid ethyl ester (2.93 g, 0.011 mol) in n-butanol (60 ml) at room temperature. The solution was heated to reflux for 16 h, cooled to room temperature and the resulting yellow solid filtered, washed with *tert*-butyl methyl ether and then dried. The

solid was redissolved in a solution of tetrahydrofuran : water (2:1; 21 ml) and lithium hydroxide (1.27 g, 0.031 mol) was then added. After stirring at room temperature for 16 h, concentrated hydrochloric acid (3 ml) was added dropwise to the mixture to precipitate a yellow solid which was filtered and dried under vacuum to give the title compound (intermediate 3) (2.32 g, 63 %) as a bright yellow solid.

Preparation of Intermediate 4

3-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride



Oxalyl chloride (20 ml, 0.2 mol) was added dropwise over 2 min to a stirred solution of 3-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid (intermediate 3) (2.0 g, 6.1 mmol) in dichloromethane (10 ml) at room temperature. *N,N*-Dimethylformamide (50µl) was then added and the resulting mixture heated to 50 °C for 1 h. The solution was then cooled to room temperature and then concentrated *in vacuo* to leave the title compound (intermediate 4) (2.0 g, 96 %) as a beige solid.

Example 50

3-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-N-(3-methoxy-propyl)-benzamide



3-Methoxypropylamine (0.026g, 0.29mmol) was added to a stirred solution of 3-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride (intermediate 4) (26 mg 0.29mmol) in tetrahydrofuran (2 ml) and the mixture stirred at room temperature for 15 min. Triethylamine (0.2 ml, 1.4 mmol) was then added and the resulting mixture stirred overnight. 1M Hydrochloric acid (3-4 ml) was added dropwise to precipitate a yellow solid which was filtered and dried under suction to give the *amide* (79 mg, 0.20 mmol) as a yellow solid, LCMS m/z 395.25 $[M+H]^+$ @ R_T 1.04 min; δ_H(400 MHz, $(CD_3)_2SO$) 8.59 (1H, m), 8.57 (1H, s), 8.39 (1H, app d *J* 9.3 Hz), 8.08 (1H, app d *J* 7.3 Hz), 7.66-7.53 (5H, m), 3.37-3.33 (4H, m), 3.27 (3H, s), 1.83-1.77 (2H, m).

Activity **

Example 51

N-Ethyl-3-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]-quinolin-2-yl)-benzamide



Prepared by the method of Example 53 substituting ethylamine for 3-methoxypropylamine.
δ_H(400 MHz, $(CD_3)_2SO$) major rotomer quoted; 8.56 (1H, br s), 8.47 (1H, m), 8.21 (2H, d *J* 8.5 Hz), 7.94 (2H, d *J* 8.5 Hz), 3.96 (3H, s), 3.31 (2H, q *J* 7.3 Hz), 2.58 (3H, s), 1.15 (3H, t *J* 7.4 Hz).

Activity **

Example 52

N-Benzyl-3-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]-quinolin-2-yl)-benzamide



Prepared by the method of Example 53 substituting benzylamine for 3-methoxypropylamine.

LCMS m/z 427.16 $[M+H]^+$ @ R_T 1.28 min.

Activity *

Examples 53 to 64 were prepared by the method of example 50, using the appropriate amine.



Example	X	R	R'	M.S. (MH+)	Activity
53	6-F	$CH_2CH_2CH_2N(Me)_2$	Me	422.5	*
54	6-F	$CH_2CH_2CH_2N(Me)_2$	H	408.4	**
55	6-F		H	420.4	*
56	6-F		H	434.4	*
57	6-F		H	448.4	**
58	6-F	$CH_2CH_2CH_2CH_2N(Me)_2$	H	422.4	**
59	6-F	CH_2CH_2OMe	H	381.3	**
60	6-F	Et	Et	379.3	*

61	6-F	CH_2CO_2Me	H	395.2	*
62	6-F	CH_2CCH	H	361.3	**
63	6-F	CH2Ph	Me	427.2	**
64	6-F			463.3	*

Example 65

N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzamide

Step 1

2-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester



A solution of 3-cyclopropyl-3-oxo-propionic acid methyl ester (6.2 g, 0.038 mols), 2-amino benzoic acid ethyl ester (4.95 g, 0.03 mols) *and p-toluene sulfonic acid* (0.04 g, 0.2 mmols) in toluene (25 ml) was heated at 125°C for 2h; 15 ml of solvent was then distilled. To the residual orange solution was added sodium ethoxide (2 M, 15 ml) in ethanol (reaction mixture turns red). This red mixture was stirred at 120°C for 2 h; 15 ml of solvent was again distilled. The reaction mixture was left to cool to room temperature, diluted with ethyl acetate (1 litre), extracted with HCl 0.1 M and water. The combined organic extracts were dried over sodium sulfate and concentrated *in vacuo* to leave an orange residue which was washed once with cold ethyl acetate to yield *2-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester* (3.87 g, 53%) as an off-white solid. LCMS m/z

244.14 $[M+H]^+$ @ R_T 0.78 min, 89%, m/z 230.11 $[Acid+H]^+$ @ R_T 1.27, 11%.

δ_H (400 MHz, $(CD_3)_2SO$) 11.04 (1 H, s), 8.06 (1 H, dd, J_1 1.1, J_2 8.1), 7.76-7.66 (2 H, m), 7.36 (1 H, td, J_1 1.1, J_2 7.5), 3.89 (3 H, s), 2.16 (1 H, m), 1.18 (4 H, d, J 7.0).

Step 2

4-Chloro-2-cyclopropyl-quinoline-3-carboxylic acid ethyl ester



Phosphorus oxychloride (0.77 ml, 0.082 mols) was added in one portion to a suspension of 2-cyclopropyl-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid ethyl ester (1.0 g, 0.041 mols) in acetonitrile and the mixture was heated at 75°C for 90 minutes (becomes a clear solution above 65°C). The resulting light brown solution was poured into saturated sodium bicarbonate (100 ml); the suspension was extracted with ethyl acetate and the combined organic extracts were dried and concentrated *in vacuo* to leave *4-Chloro-2-cyclopropyl-quinoline-3-carboxylic acid ethyl ester* (1.15 g, 106 %) as an off-white solid. R_f (AcOEt) = 0.73.

Step 3

4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid

23



4-Chloro-2-cyclopropyl-quinoline-3-carboxylic acid ethyl ester (1.15 g, 0.0041 mols) and 4-hydrazino-benzoic acid (1.0g, 0.0068 mols) were stirred in ethanol (30 ml) at reflux for 16 h. The bright yellow suspension was diluted with heptane, filtered, washed with cold *t*-butylmethyl ether and left to dry under suction to yield crude solid containing hydrazine. This solid was suspended in 1 M HCl, filtered, washed with water and then dried *in vacuo* to yield *4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid* (1.135 g, 80 %) as a yellow solid, LCMS m/z 346.20 $[M+H]^+$ @ R_T 1.05 min: 96% purity.

δ_H (400 MHz, $(CD_3)_2SO$) 11.4 (1 H, s), 8.43 (2 H, d, *J* 8.1), 8.21 (1 H, dd, J_1 1.2, J_2 8.1), 8.07 (2 H, d, *J* 8.1), 7.92 (1 H, d, *J* 8.1), 7.67 (1 H, t, *J* 6.6), 7.52 (1 H, t, *J* 6.5), 3.43 (1 H, m), 1.59 (2 H, m), 1.43 (2 H, m).

Step 4

4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]-quinolin-2-yl)-benzoyl chloride

24



To a suspension of finely ground 4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoic acid (0.19 g. 0.55 mmol) in dichloromethane (4 ml) was added oxalyl chloride (1.6 ml, 0.01 mol) followed by a drop of dimethyl formamide. The mixture was stirred under nitrogen at 45 °C for 8 h. The solvent was removed in vacuo to yield *4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride* as a pale yellow solid, LCMS m/z $[M+MeOH-Cl]^+$ @ R_T 1.46 min: 95% purity. Used without further purification.

Step 5

N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzamide



To a partial solution of 4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-benzoyl chloride (0.1 g, 0.28 mmol) in tetrahydrofurane (6 ml) under nitrogen was added a solution of 3-dimethylamino-propyl

amine (0.03 g, 0.3 mmol) in tetrahydrofurane (3 ml). The mixture was stirred at RT for 3 h. The solvent was removed under reduced pressure and the yellow solid was washed with a little saturated sodium bicarbonate, water and dried under vacuo to yield *N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]-quinolin-2-yl]-benzamide* (57 mg, 47 %) as a yellow solid. LCMS m/z 430.11 $[M+H]^+$ @ R_T 0.99 min: 100% purity.

Activity ***

Preparation of Intermediate 5

4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzoyl chloride



To a suspension of finely ground 4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzoic acid (1.1 g. 3.4 mmol) in dichloromethane (6 ml) was added oxalyl chloride (2.4 ml, 29 mmol) followed by a drop of dimethyl formamide. The mixture was stirred under nitrogen at 45 °C for 3 h. The solvent was removed in vacuum to yield *4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzoyl chloride* (1.15 g, quantitative) as a pale yellow solid that was used without further purification.

Example 66

N-(3-Dimethylamino propyl)-4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzamide hydrochloride



To a partial solution of 4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzoyl chloride (0.1 g, 0.3 mmol) in tetrahydrofurane (5 ml) under nitrogen was added a solution of 3-dimethylamino-propyl amine (0.03 g, 0.3 mmol) in tetrahydrofurane. The mixture was stirred at rt for 90 minutes. The solvent was removed under reduced pressure and the yellow solid was purified *via* FCC silica gel (gradient elution, MeOH:H_2O, Fluka C_{18} reverse phase) to yield *N-(3-Dimethylamino propyl)-4-(6-fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzamide hydrochloride* (70 mg, 53 %) as a yellow solid.

LCMS m/z 408.39 $[M+H]^+$ @ R_T 0.89 min: 90% purity.

Activity ***

Exmaples 67 - 141 were prepared analogously from the appropriate benzoyl chloride and the appropriate amine



Example	X	Z	W	R	R'	M.S. (MH+)	Activity
67	6-F	H	H	$-CH_2CH_2CH_2CH_2CH_2-$		391.3	**
68	6-F	H	H	$-CH_2$Phenyl	H	413.2	***
69	6-F	H	H	$-CH_2$Phenyl	Me	427.3	**
70	6-F	H	H	$-CH_2CH_2OMe$	H	381.2	***
71	6-F	H	H	$-CH_2CH_2N(Me)_2$	H	394.3	***
72	6-F	H	H	$-CH_2CO_2Me$	H	395.3	***
73	6-F	H	H	$-CH_2CH_2CH_2OMe$	H	395.2	***
74	6-F	H	H	$-CH_2CH_2CH_2N(Me)_2$	H	408.3	***
75	6-F	H	H		H	431.3	**
76	6-F	H	H		H	419.2	**
77	6-F	H	H	Et	H	351.2	***
78	6-F	H	H	Et	Et	379.3	**
79	6-F	H	H		H	420.4	***
80	6-F	H	H	$-CH_2CH_2CH_2N(Me)_2$	Me	422.4	***
81	6-F	H	H	-CH2CH2CH2CH2N(Me)2	H	422.4	***
82	6-F	H	H		H	448.5	***
83	6-F	H	H		H	434.4	***
84	6-F	H	H		H	525.3	***
85	6-F	H	H	$-CH_2CH_2CH_2CH_2CH_2N(Me)_2$	H	450.3	***
86	H	H	H	$-CH_2CH_2CH_2N(Me)_2$	H	390.2	***
87	H	H	H	$-CH_2CH_2CH_2CH_2CH_2N(Me)_2$	H	432.1	**

88	H	H	H	$-CH_2CH_2CH_2CH_2N(Et)_2$	H	432.2	**
89	H	H	H	$-CH_2CH_2CH_2N(Me)_2$	Me	404.2	**
90	6-F	H	2-Cl	$-CH_2CH_2CH_2N(Me)_2$	H	442.1	**
91	H	H	H		H	416.1	**
92	H	H	H		H	573.0	**
93	H	H	H		H	445.1	**
94	H	H	H		H	507.1	**
95	6-F	H	H		H	591.0	***
96	H		H	$-CH_2CH_2CH_2N(Me)_2$	H	430.1	***
97	6-F	H	H		H	464.1	***
98	6-F	H	H		H	463.1	***
99	6-F	H	3-Cl		H	482.1	**
100	6-F	H	2-Cl		H	497.1	**
102	6-F	H	2-Cl	$-CH_2CH_2CH_2CH_2N(Et)_2$	H	484.1	**
103	6-F	H	3-Cl	$-CH_2CH_2CH_2N(Me)_2$	H	442.1	**
104	H		H		H	470.4	***

105	6-F	H	H			516.3	*
106	6-F	H	H		H	470.3	***
107	6-F	H	H	$-CH_2CH_2N(iPr)_2$	H	451.4	***
108	6-F	H	2-Cl		H	496.2	**
109	6-F	H	H		H	456.1	***
110	6-F	H	2-Cl	$-CH_2CH_2CH_2CH_2N(Me)_2$	H	456.1	**
111	6-F	H	H			406.2	**
112	6-F	H	H		H	462.1	***
113	6-F	H	H		H	436.1	***
114	6-F	H	H		H	434.4	***
115	6-F	H	H		H	476.1	***
116	6-F	H	H		H	496.1	***
117	6-F	H	H		H	436.3	***

118	6-F	H	H		H	462.3	***
119	6-F	H	H		H	428.1	**
120	6-F	H	H	$-CH_2CH_2SEt$	H	411.3	***
121	6-F	H	H		H	448.3	**
122	6-F	H	H		H	431.3	***
123	6-F	H	H		H	434.3	**
124	6-F	H	H	$-CH_2CH_2CH_2CH_2N(Et)_2$	H	450.4	***
125	6-F		H		H	536.1	***
126	6-F		H		H	516.2	***
127	6-F	H	H		H	428.3	*
128	6-F	H	H	$-CH_2CH_2CH_2SMe$	H	411.3	**
129	H		H		H	498.5	***
130	6-F		H		H	488.4	***
131	6-F	H	H		H	446.3	***

132	6-F		H	$-CH_2CH_2CH_2N(Me)_2$	H	448.2	***
133	6-F		H		H	502.3	***
134	6-F		H		H	486.3	***
135	6-F		H	$-CH_2CH_2CH_2CH_2N(Et)_2$	H	490.3	***
136	6-F		H		H	546.2	**
137	6-F		H		H	631.2	***
138	6-F		H		H	468.2	**
139	6-F		H		H	468.2	*
140	6-F		H		H	476.2	***
141	6-F		H		H	474.3	***

Example 142

{3-[4-(6-Fluoro-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl)-phenyl]-ureido} acetic acid ethyl ester



Ethyl cyanatoacetate (31 mg, 0.24 mmol) was added in one portion to a stirred solution of 2-(4-aminophenyl)-6-fluoro-2,5-dihydropyrazolo[4,3-c]quinolin-3-one (intermediate 2) (50 mg, 0.17 mmol) in *N*, *N*-dimethylformamide (2 ml) and the mixture stirred at *room temperature for 16* h. Water (1 ml) was then added to the mixture to precipitate a solid, which was filtered, washed with water (1 ml) and then ethyl acetate (1 ml) and finally dried by suction to leave the *urea* as a yellow solid, LCMS m/z 424.40 $[M+H]^+$ @ R_T 1.06 min.

Activity ***

Examples 143 and 144



Example 143
LCMS m/z 438.41 $[M+H]^+$ @ RT 1.13 min.

Activity **



Example 144
LCMS m/z 514.46 $[M+H]^+$ @ RT 1.35 min.

Activity *

The following compounds were synthesised by the method of Example 142, substituting the appropriate isocyanate, isothiocyanate or chloroformate for ethyl cyanatoacetate.



Example	X	Z	Y	R	A	M.S. (MH+)	Activity
144	6-F	H	O	iPr	NH	380.3	***
145	6-F	H	O	nPr	NH	380.3	***
146	6-F	H	O	tBu	NH	394.4	***
147	6-F	H	O	Ph	NH	414.3	**
148	6-F	H	S		NH	394.3	**
149	6-F	H	S		NH	436.4	*
150	6-F	H	O	tBu	O	395.3	***
151	6-F	H	O	Et	O	367.2	**
152	6-F	H	O	$CH_2CH_2N(Me)_2$	O	410.2	***
153	H		O	Me	O	375.3	**
154	6-F	H	O	$CH_2CH_2CH_2N(Me)_2$	O	424.1	***
155	6-F	H	O		O	512.3	**
156	6-F	H	S	nPentyl	NH	424.4	**
157	6-F	H	S	$CH(CH_3)CH(CH_3)CH_3$	NH	424.4	**
158	6-F	H	O	$CH_2CH_2CH_2CH_2N(Et)_2$	NH	465.4	***
159	H	H	O	nPr	NH	362.3	***
160	H	H	S		NH	376.1	**

161	6-F	H	O	$CH_2CH_2CH_2N(Me)_2$	NH	423.3	***
162	H	H	O		NH	434.5	***
163	6-F	H	O	$CH_2CH_2CH_2CH_2N(Me)_2$	NH	437.2	***
164	6-F	H	O		NH	463.5	***

Intermediate 6: Preparation of methyl 4-oxothiochromane-3-carboxylate



Dry tetrahydrofuran (60 ml) was cooled under nitrogen atmosphere to -50 to -60°C. 1M Lithium bis(trimethylsily)amide solution in hexane (56 ml, 56 mmol) was added. The temperature was kept at -50 to -60°C and thiochroman-4-one was added dropwise over 20 min. Stirring was continued at low temperature for 60 min. Methyl cyanoformate (4.84 ml, 60.9 mmol) was added dropwise over 5 min to the reaction mixture. The obtained suspension was stirred at -50 to -60°C for 80 min and then allowed to warm up to room temperature. Saturated ammonium chloride solution (100 ml) was added. The phases were separated, the aqueous phase extracted with ethyl acetate (2 x 100 ml). The combined organic phases were washed with water (50 ml), dried over magnesium sulphate, filtered and concentrated under vacuum. An orange oil was obtained and purified by column chromatography. The title

compound was isolated as a yellow solid (4.70 g, 21.1 mmol, 42%). LCMS: m/z 221 $[M-H]^+$.

Intermediate 7: Preparation of 4-(3-Oxo-3a,4-dihydro-3H-thiochromeno[4,3-c]pyrazol-2-yl)-benzoic acid



4-Oxothiochromane-3-carboxylate (0.50 g, 2.25 mmol) and hydrazinobenzoic acid (0.377 g, 2.48 mmol) were mixed in acetic acid (6 ml). The mixture was heated to reflux for 30 min. Excess acetic acid was distilled off to give a brown oil. Diethylether was added, a precipitate formed which was collected by filtration and dried under vacuum. The crude product was isolated as a red/brown solid (797 mg). LCMS: m/z 325 $[M+H]^+$. No purification was carried out.

Intermediate 8: Preparation of 4-(3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzoic acid



Crude 4-(3-Oxo-3a,4-dihydro-3H-thiochromeno[4,3-c]pyrazol-2-yl)-benzoic acid (250 mg, 0.77 mmol) was dissolved in dimethyl sulphoxide (6 ml). O-Chloranil (189 mg, 0.77 mmol) was added and the mixture was stirred at room temperature overnight. Water (20 ml) was added and the solids were collected by filtration and washed with water. The filter cake was triturated with toluene, filtered and dried under vacuum. The title compound was isolated as a dark brown solid (230 mg, 0.71 mmol, 92%). LCMS: m/z 323 $[M+H]^+$

Alternatively crude 4-(3-Oxo-3a,4-dihydro-3H-thiochromeno[4,3-c]pyrazol-2-yl)-benzoic acid can be stirred in dimethyl sulphoxide under exposure to air. It was found that air oxidation provides clean product, however the reaction is much slower.

Example 165

Preparation of *N*-[3-(dimethylamino)propyl]-4-(3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzamide



4-(3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzoic acid (55 mg, 0.17 mmol) was suspended in anhydrous dimethyl acetamide (1 ml). Diisopropyl-ethyl amine (46.5 mg, 0.36 mmol, 62μl) was added followed by 3-dimethylaminopropylamine (17.5 mg, 0.17 mmol) and [(benzotriazol-1-yloxy)-dimethylamino-methylene]-dimethyl-ammonium hexafluoro phosphate (65 mg, 0.17 mmol). The mixture was stirred at room temperature for 4 h and was purified by preparative HPLC. The title compound was isolated as a brown solid. LCMS: m/z 407 $[M+H]^+$

Activity **

Example 166

Preparation of *N*-[(cyclohexylamino)propyl]-4-(3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzamide



The reaction was carried out as described above. LCMS: m/z 461 $[M+H]^+$

Activity ***

Example 167

Preparation of *N*-(pyrrolidin-1-yl-butyl)-4-(3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzamide



The reaction was carried out as described above. LCMS: m/z 447 $[M+H]^+$

Activity *

Example 168

Preparation of 4-(3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)-*N*-1,2,2,6,6-pentamethylpiperidin-4-ylbenzamide



The reaction was carried out as described above. LCMS: m/z 475 $[M+H]^+$

Activity **

Intermediate 9: Preparation of 3-[(2-fluorophenyl)sulfanyl]propanoic acid



2-Fluorothiophenol (5.0 g, 39 mmol) was dissolved in tetrahydrofuran (50 ml) under a nitrogen atmosphere. Triethylamine (3.94 g, 5.33 ml, 85.8 mmol) was added. Acrylic acid (2.81 g, 2.67 ml, 39 mmol) was dissolved in tetrahydrofuran and added dropwise to the reaction solution over 2 h at room temperature. The mixture was stirred at room temperature overnight. 1M Hydrochloric acid (50 ml) was added and the phases were separated. The aqueous phase was washed with ethyl acetate (2 x 50 ml). The combined organic phases were dried over magnesium sulphate, filtered and concentrated under vacuum. A

yellow oil was obtained which solidified upon storage at room temperature. The solid was triturated with hexane, filtered and dried under vacuum. The title compound was isolated as an off-white solid (4.19 g, 20.9 mmol, 54%).

Intermediate 10: Preparation of 8-fluoro-2,3-dihydro-4*H*-thiochromen-4-one



3-[(2-Fluorophenyl)sulfanyl]propanoic acid (4.0 g, 20 mmol) was mixed with concentrated sulphuric acid (20 ml) at 0-5°C. The reaction solution was stirred at 0 to 5°C for 3 h then allowed to warm up to room temperature overnight. The mixture was quenched dropwise into ice to give a white suspension. The aqueous phase was extracted with ethyl acetate (1 x 200 ml, 1 x 100 ml). The combined organic phases were washed with saturated sodium bicarbonate solution (1 x 50 ml), water (1 x 50 ml), 1M hydrochloric acid (50 ml) and water (2 x 50 ml). The organic phase was dried over magnesium sulphate, filtered and concentrated under vacuum. The title compound was isolated as a yellow solid (2.10 g, 11.5 mmol, 58%).

Intermediate 11: Preparation of methyl 8-fluoro-4-oxothiochromane-3-carboxylate



1M Lithium hexamethyldisilazide solution in hexane (13.2 ml) was dissolved in anhydrous tetrahydrofuran (20 ml) under nitrogen atmosphere. The solution was cooled to -78°C. 8-Fluoro-2,3-dihydro-4*H*-thiochromen-4-one (2.00 g, 11 mmol) was dissolved in tetrahydrofuran (40 ml), the solution was transferred to the dropping funnel and added dropwise over 30 min to the reaction mixture maintaining the temperature below -60°C. An orange clear solution was obtained which was stirred at -78°C to -65°C for 2 h. Methyl cyanoformate (0.935 g, 0.87 ml) was dissolved in tetrahydrofuran (2 ml) and added dropwise to the reaction solution. Stirring was continued at low temperature for 1 h, the mixture was then allowed to warm to room temperature. Saturated ammonium chloride solution (20 ml) and water (10 ml) were added, the phases mixed for 5 min and separated. The aqueous phase was washed with ethyl acetate (2 x 100 ml) and the combined organic phases were dried over magnesium sulphate. The mixture was filtered and the solvent removed under vacuum to give an orange oil. The crude oil was purified by column chromatography; mobile phase: hexanes, gradient to hexanes / ethyl acetate [90:10]. The title compound was isolated as a yellow solid (1.19 g, 4.95 mmol, 45%).

Intermediate 12: Preparation of 4-(6-fluoro-3-oxothiochromeno[4,3-c]pyrazol-2(3*H*)-yl)benzoic acid



Methyl 8-fluoro-4-oxothiochromane-3-carboxylate (1.19 g, 4.95 mmol) and 4-hydrazinobenzoic acid (755 mg, 4.95 mmol) were mixed with glacial acetic acid (10 ml). The mixture was heated to reflux for 4 h. Excess acetic acid was removed under vacuum to give an orange oil. Ethyl acetate (10 ml) was added and the mixture sonicated. Precipitation of an orange solid was observed. The solids were collected by filtration and washed with ethyl acetate. The filter cake was taken up in dimethyl suphoxide (10 ml) and air-oxidised at room temperature for one week. Water (20 ml) was added to the reaction mixture, the solids were collected by filtration, slurried in ethyl acetate, filtered and dried under vacuum. The title compound was isolated as an orange powder (175 mg, 0.51 mmol, 10%). LCMS: m/z 341.

Example 169

Preparation of *N*-[3-(dimethylamino)propyl]-4-(6-fluoro-3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzamide



4-(6-Fluoro-3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzoic acid (41 mg, 0.12 mmol) was dissolved in anhydrous dimethyl-acetamide(1 ml). Diisopropyl-ethyl amine (46 mg, 0.36 mmol, 62μl) was added followed by [(benzotriazol-1-yloxy)-dimethylamino-methylene]-dimethyl-ammonium hexafluoro phosphate (65 mg, 0.17 mmol) and 3-dimethylaminopropylamine (12 mg, 0.12 mmol). The mixture was stirred at room temperature overnight and purified by preparative HPLC. The title compound was isolated as a brown solid. LCMS: m/z 425 $[M+H]^+$.

Activity **

Example 170

Preparation of *N*-[(cyclohexylamino)propyl]-4-(6-fluoro-3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzamide



The reaction was carried out as described above. LCMS: m/z 479 $[M+H]^+$.

Activity **

Example 171

Preparation of *N*-(pyrrolidin-1-yl-butyl)-4-(6-fluoro-3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)benzamide



The reaction was carried out as described above. LCMS: m/z 465 $[M+H]^+$.

Activity ***

Example 173

Preparation of 4-(6-fluoro-3-oxothiochromeno[4,3-*c*]pyrazol-2(3*H*)-yl)-*N*-1,2,2,6,6-pentamethylpiperidin-4-ylbenzamide



The reaction was carried out as described above. LCMS: m/z 493 $[M+H]^+$

Activity ***

Assay Section

The examples described above were tested in a cell free Homogenous Time Resolved Fluorescence (HTRF) assay to determine their activity as inhibitors of the CD80-CD28 interaction.

In the assay, europium and allophycocyanin (APC) are associated with CD28 and CD80 indirectly (through antibody linkers) to form a complex, which brings the europium and APC into close proximity to generate a signal. The complex comprises the following six proteins: fluorescent label 1, linker antibody 1, CD28 fusion protein, CD80 fusion protein, linker antibody 2, and fluorescent label 2. The table below describes these reagents in greater detail.

Fluorescent label 1	Anti-Rabbit IgG labelled with Europium (1μg/ml)
Linker antibody 1	Rabbit IgG specific for mouse Fc fragment (3μg/ml)
CD28 fusion protein	CD28 - mouse Fc fragment fusion protein (0.48μg/ml)

CD80 fusion protein	CD80 mouse Fab fragment (C215) fusion protein (1.9μg/ml)
Linker antibody 2	GαMκ-biotin: biotinylated goat IgG specific for mouse kappa chain (2μg/ml)
Fluorescent label 2	SA-APC: streptavidin labelled allophycocyanin (8μg/ml)

On formation of the complex, europium and APC are brought into proximity and a signal is generated.

Non-specific interaction was measured by substituting a mouse Fab fragment (C215) for the CD80 mouse Fab fragment fusion protein (1.9μg/ml). The assay was carried out in black 384 well plates in a final volume of 30μl. Assay buffer: 50mM Tris-HCl, 150mM NaCl pH7.8, containing 0.1% BSA (w/v) added just prior to use.

Compounds were added to the above reagents in a concentration series ranging between 100μM - 1.7nM. The reaction was incubated for 4 hours at room temperature. Dual measurements were made using a Wallac Victor 1420 Multilabel Counter. First measurement: excitation 340nm, emission 665nm, delay 50μs, window time 200μs. second measurement: excitation 340nm, emission 615nm, delay 50μs, window time 200μs. Counts were automatically corrected for fluorescence crossover, quenching and background.

By way of illustration, the EC_{50} results for the compounds of Examples 15, 21, 29, 35 and 83 were 8 μM, 1.9 μM, 950 nM, 148nM and 90nM respectively. For convenience, the EC50 activities of compounds tested are recorded above in summary form as:

EC50: * = >10 μM, ** = 1-10 μM, *** = <1 μM.

CLAIMS

1. A compound of formula (I) or a pharmaceutically or veterinarily acceptable salt thereof:



(I)

wherein

R_1 and R_3 independently represent H; F; Cl; Br; $-NO_2$; $-CN$; C_1-C_6 alkyl optionally substituted by F or Cl; or C_1-C_6 alkoxy optionally substituted by F;

R_2 represents H, or optionally substituted C_1-C_6 alkyl, C_3-C_7 cycloalkyl or optionally substituted phenyl;

Y represents -O-, -S-, N-oxide, or $-N(R_5)-$ wherein R_5 represents H or C_1-C_6 alkyl;

X represents a bond or a divalent C_1-C_6 alkylene radical;

R_4 represents $-C(=O)NR_6R_7$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$, $-NHC(=O)NHR_6$ or $-NHC(=S)NHR_6$ wherein

R_6 represents H, or a radical of formula $-(Alk)_b-Q$ wherein b is 0 or 1 and

Alk is an optionally substituted divalent straight chain or branched C_1-C_{12} alkylene, C_2-C_{12} alkenylene or C_2-C_{12} alkynylene radical which may be interrupted by one or more non-adjacent -O-, -S- or $-N(R_8)-$ radicals wherein R_8 represents H or C_1-C_4 alkyl, C_3-C_4 alkenyl, C_3-C_4 alkynyl, or C_3-C_6 cycloalkyl, and

Q represents H; $-CF_3$; -OH; -SH; $-NR_8R_8$ wherein each R_8 may be the same or different; an ester group; or an optionally substituted phenyl, C_3-C_7 cycloalkyl, C_5-C_7 cycloalkenyl or heterocyclic ring having from 5 to 8 ring atoms; and

R_7 represents H or C_1-C_6 alkyl; or when taken together with the atom or atoms to which they are attached R_6 and R_7 form an optionally substituted heterocyclic ring having from 5 to 8 ring atoms.

2. A compound as claimed in claim 1 wherein R_1 is H, F, Cl, methyl or methoxy.

3. A compound as claimed in claim 1 or claim 2 wherein R_2 is H, methyl, methoxy, cyclopropyl, phenyl, or fluoro-, chloro-, methyl, or methoxy-substituted phenyl.

4. A compound as claimed in any of the preceding claims wherein R_3 is H, F, Cl, methyl, methoxy, or methylenedioxy.

5. A compound as claimed in any of the preceding claims wherein Y is -O-, -S-, or $-N(R_5)-$ wherein R_5 represents H or methyl.

6. A compound as claimed in any of the preceding claims wherein X is a bond, or a $-CH_2-$ or $-CH_2CH_2-$ radical.

7. A compound as claimed in any of the preceding claims wherein R_4 represents $-C(=O)NHR_6$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$, $-NHC(=O)NHR_6$ or $-NHC(=S)NHR_6$ and in these R_6 is H or a radical of formula $-Alk_b-Q$ wherein

b is 0 or 1 and

Alk is a $-(CH_2)_n-$, $-CH((CH_2)_mCH_3)(CH_2)_n-$, $-CH((CH_2)_mCH_3)((CH_2)_pCH_3)(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_m-$, or $-(CH_2)_n-O-(CH_2)_n-O-(CH_2)_m-$, radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and Q represents H, -OH, $-COOCH_3$ phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl. and

R_7 is H, or when taken together with the nitrogen atom to which they are attached R_6 and R_7 form a pyrrolidine-2-one or pyrrolidine-2,5-dione ring.

8. A compound as claimed in claim 1 wherein R_1 is H, F, or Cl; R_2 is H; R_3 is H, F, or Cl; Y is-NH-; X is a bond; and R_4 represents $-C(=O)NHR_6$, $-NR_7C(=O)R_6$, $-NR_7C(=O)OR_6$ or $-NHC(=O)NHR_6$ wherein:

R_6 is H or a radical of formula $-Alk_b-Q$ wherein b is 0 or 1 and

Alk is a $-(CH_2)_n-$, $-CH((CH_2)_mCH_3)(CH_2)_n-$, $-CH((CH_2)_mCH_3)((CH_2)_pCH_3)(CH_2)_n-$, $-(CH_2)_n-O-(CH_2)_m-$, or $-(CH_2)_n-O-(CH_2)_n-O-(CH_2)_m-$, radical where n is 1, 2, 3 or 4 and m and p are independently 0, 1, 2, 3 or 4, and Q represents H, -OH, $-COOCH_3$ phenyl, cyclopropyl, cyclopentyl, cyclohexyl, pyridyl, furyl, thienyl, or oxazolyl. and

R_7 is H, or when taken together with the nitrogen atom to which they are attached R_6 and R_7 form a pyrrolidine-2-one or pyrrolidine-2,5-dione ring.

9. A compound as claimed in claim 1 wherein R_1 is F, R_2 is H or cyclopropyl, R_3 is H, X is a bond, and R4 is $-C(=O)NHR_6$, $-NRHC(=O)R_6$, or $-NHC(=O)NHR_6$.

10. N-(3-Dimethylamino propyl)-4-(4-cyclopropyl-3-oxo-3,5-dihydro-pyrazolo[4,3-c]quinolin-2-yl]-benzamide, or pharmaceutically or veterinarily acceptable salt thereof.

11. A compound as claimed in any of claims 1 to 10 for use in the treatment of conditions which benefit from immunomodulation.

12. The use of a compound as claimed in any of claims 1 to 10 in the manufacture of a medicament for the treatment of conditions which benefit from immunomodulation.

13. A method of immunomodulation in humans and non-human primates, comprising administration to a subject in need of such treatment an immunomodulatory effective dose of a compound as claimed in any of claims 1 to 10.

14. A pharmaceutical or veterinary composition comprising a compound as claimed in any of claims 1 to 10 together with a pharmaceutically or veterinarily acceptable excipient or carrier.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2003/001805

A. CLASSIFICATION OF SUBJECT MATTER

IPC7: C07D 471/06, A61K 31/437, A61P 37/02
According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC7: C07D

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

SE,DK,FI,NO classes as above

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

CHEM. ABS DATA, WPI DATA, EPO-INTERNAL

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
PX	WO 03004495 A1 (ACTIVE BIOTECH AB), 16 January 2003 (16.01.2003)	1-14
	--	
X	WO 9111448 A1 (THE BOOTS COMPANY PLC), 8 August 1991 (08.08.1991), see the claims	1-14
	--	
X	WO 9734893 A1 (ASTRA PHARMACEUTICALS LTD.), 25 Sept 1997 (25.09.1997)	1-14
	--	

☐ Further documents are listed in the continuation of Box C. ☒ See patent family annex.

* Special categories of cited documents:
"A" document defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent but published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed
"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search	Date of mailing of the international search report
5 February 2004	17 -02- 2004
Name and mailing address of the ISA/ Swedish Patent Office Box 5055, S-102 42 STOCKHOLM Facsimile No. +46 8 666 02 86	Authorized officer Carolina Gómez Lagerlöf/EÖ Telephone No. +46 8 782 25 00

Form PCT/ISA/210 (second sheet) (January 2004)

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2003/001805

Box No. II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.: 13
because they relate to subject matter not required to be searched by this Authority, namely:

see next sheet

2. ☐ Claims Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box No. III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐ The additional search fees were accompanied by the applicant's protest.

☐ No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.
PCT/SE 2003/001805

Box No. IV Text of the abstract (Continuation of item 5 of the first sheet)

Claim 13 relates to a method of treatment of the human or animal body by surgery or by therapy/a diagnostic method practised on the human or animal body/Rule 39.1(iv). Nevertheless, a search has been executed for this claim. The search has been based on the alleged effects of the compound/composition.

WO	03004495	A1	16/01/2003	AU	1290302	A	15/05/2002
				SE	0102404	D	00/00/0000
				US	6642249	B	04/11/2003
				US	2003022913	A	30/01/2003
WO	9111448	A1	08/08/1991	AU	7220991	A	21/08/1991
				BR	9105984	A	10/11/1992
				CA	2074841	A	03/08/1991
				CS	9100238	A	15/09/1991
				EP	0539372	A	05/05/1993
				FI	923486	A	31/07/1992
				GB	9002314	D	00/00/0000
				HU	9202510	D	00/00/0000
				IE	910365	A	14/08/1991
				IL	97114	D	00/00/0000
				IN	171735	A	26/12/1992
				JP	5505180	T	05/08/1993
				MX	24401	A	01/10/1993
				NO	923037	A	30/09/1992
				PT	96656	A	31/10/1991
				ZA	9100764	A	30/10/1991
				GB	9002315	D	00/00/0000
				GB	9002425	D	00/00/0000

WO	9734893	A1	25/09/1997	AU	712141	B	28/10/1999
				AU	2186797	A	10/10/1997
				BR	9708103	A	27/07/1999
				CA	2247814	A	25/09/1997
				CN	1218472	A	02/06/1999
				CZ	9802977	A	17/03/1999
				EE	9800298	A	15/02/1999
				EP	0888347	A	07/01/1999
				GB	9605803	D	00/00/0000
				ID	16283	A	00/00/0000
				IL	126271	D	00/00/0000
				JP	2000506884	T	06/06/2000
				NO	984290	A	27/10/1998
				NZ	331614	A	28/07/2000
				PL	328921	A	01/03/1999
				SK	118798	A	10/03/1999
				TR	9801861	T	00/00/0000
				ZA	9702150	A	22/09/1997
				GB	9610474	D	00/00/0000
				GB	9610894	D	00/00/0000
				AU	719553	B	11/05/2000
				AU	2170397	A	22/10/1997
				BR	9708478	A	13/04/1999
				DE	69709075	D,T	22/08/2002
				DK	890013	T	08/04/2002
				EP	0890013	A,B	13/01/1999
				SE	0890013	T3	
				GB	9700862	D	00/00/0000
				NO	984548	A	27/11/1998
				US	6170578	B	09/01/2001